Biomarin Plans to Test Two Doses of BMN 270 in Phase 3 Trials for Treatment of Hemophilia A
News
BioMarin Pharmaceutical will add an additional Phase 3 study to the clinical development of its investigational gene therapy BMN 270 for hemophilia A. BioMarin will conduct two separate trials testing ... Read more